Advances in nuclear technology and the development of new production methods have made it possible to produce the MIRD-237 on a large scale. Today, the isotope is produced through the irradiation of Ytterbium-176 with neutrons in a nuclear reactor or through the proton bombardment of Ytterbium-176 in a particle accelerator.
The development of the MIRD-237 as a therapeutic agent was a result of extensive research and collaboration between nuclear medicine physicians, oncologists, and radiopharmaceutical manufacturers. The isotope was initially produced through the irradiation of Ytterbium-176 with neutrons in a nuclear reactor. However, this method had limitations, including low yields and high production costs. MIRD-237
The MIRD-237, a term that may seem unfamiliar to many, is a radioactive isotope that has been extensively used in the field of nuclear medicine and radiation therapy. This article aims to provide a comprehensive review of the MIRD-237, including its history, development, and applications. Advances in nuclear technology and the development of